A comparison of existing risk prediction models in patients undergoing venoarterial extracorporeal membrane oxygenation by Worku, B. et al.
Journal Articles 
2020 
A comparison of existing risk prediction models in patients 






See next page for additional authors 
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles 
 Part of the Cardiology Commons, and the Surgery Commons 
Recommended Citation 
Worku B, Gaudino M, Avgerinos D, Ramasubbu K, Gambardella I, Gulkarov I, Khin S. A comparison of 
existing risk prediction models in patients undergoing venoarterial extracorporeal membrane 
oxygenation. . 2020 Jan 01; ():Article 6080 [ p.]. Available from: 
https://academicworks.medicine.hofstra.edu/articles/6080. Free full text article. 
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic 
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara 
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu. 
Authors 
B. Worku, M. Gaudino, D. Avgerinos, K. Ramasubbu, I. Gambardella, I. Gulkarov, and S. Khin 
This article is available at Donald and Barbara Zucker School of Medicine Academic Works: 
https://academicworks.medicine.hofstra.edu/articles/6080 
A comparison of existing risk prediction models in patients undergoing
venoarterial extracorporeal membrane oxygenation
Berhane Workua,b,*, Mario Gaudinob, Dimitrios Avgerinosb, Kumudha Ramasubbuc,
Ivancarmine Gambardellaa,b, Iosif Gulkarova,b, Sandi Khinc
aDepartment of Cardiothoracic Surgery, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, 11215, USA
b Department of Cardiothoracic Surgery, New York Presbyterian Weil Cornell Medical Center, New York, NY, 10021, USA
c Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, 11215, USA
A R T I C L E I N F O
Article History:
Received 2 February 2020
Revised 1 March 2020
Accepted 5 March 2020
Available online xxx
A B S T R A C T
Background: Patients undergoing consideration for venoarterial extracorporeal membrane oxygenation
(VA-ECMO) require an immediate risk profile assessment in the setting of incomplete information. A number
of survival prediction models for critically ill patients and patients undergoing elective cardiac surgery or
institution of VA-ECMO support have been designed. We assess the ability of these models to predict out-
comes in a cohort of patients undergoing institution of VA-ECMO for cardiogenic shock or cardiac arrest.
Methods: Fifty-one patients undergoing institution of VA-ECMO support were retrospectively analyzed.
APACHE II, SOFA, SAPS II, Encourage, SAVE, and ACEF scores were calculated. Their ability to predict outcomes
were assessed.
Results: Indications for ECMO support included postcardiotomy shock (25%), ischemic etiologies (39%), and
other etiologies (36%). Pre-ECMO arrest occurred in 73% and 41% of patients underwent cannulation during
arrest. Survival to discharge was 39%. Three survival prediction model scores were significantly higher in
nonsurvivors to discharge than surivors; the Encourage score (25.4 vs 20; p = .04), the APACHE II score
(23.6 vs 19.2; p = .05), and the ACEF score (3.1 vs 1.8; p = .03). In ROC analysis, the ACEF score demonstrated
the greatest predictive ability with an AUC of 0.7.
Conclusions: A variety of survival prediction model scores designed for critically ill ICU and VA-ECMO patients
demonstrated modest discriminatory ability in the current cohort of patients. The ACEF score, while not
designed to predict survival in critically ill patients, demonstrated the best discriminatory ability. Further-
more, it is the simplest to calculate, an advantage in the emergent setting.







Venoarterial extracorporeal membrane oxygenation (VA-ECMO)
is increasingly utilized in the setting of cardiogenic shock to provide
hemodyamic and respiratory support to the acutely decompensating
patient. Common scenarios include cardiogenic shock following acute
myocardial infarction, acute exacerbation of chronic congestive heart
failure, myocarditis, and postcardiotomy shock among others.1 This
extremely aggressive therapy can be life-saving when appropriately
applied, but inappropriate use can lead to unnecessary prolongation
of patient and family suffering and significant costs and resource
utilization.2-4
Prognosis after institution of VA-ECMO support is heavily depen-
dent on a patient’s comorbidities and degree of decompensation prior
to institution of mechanical support. Numerous survival prediction
models exist for critically ill patients (APACHE II [acute physiology
and chronic health evaluation II], SAPS II [simplified acute physiology
II], SOFA [sequential organ failure assessment] scores) as well as for
patients undergoing elective cardiac surgery (ACEF [age, creatine,
ejection fraction] score). These scores have demonstrated variable
results in patients undergoing institution of VA-ECMO support.5-9
While several institutional studies and few registry studies have
described predictors of survival after VA ECMO for cardiogenic shock
or cardiac arrest,10-12 very few survival prediction models specifically
designed for VA-ECMO exist, with varying degrees of complexity.5-
9,13-14 We describe our experience with VA ECMO for cardiogenic
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shock and cardiac arrest with the goal of comparing the utility of the
previously described survival prediction models for critically ill
patients and patients undergoing institution of VA-ECMO support.
Patients and methods
This was a retrospective study of all patients undergoing institu-
tion of VA-ECMO support at our institution from 2010 to 2017. Data
regarding pre-ECMO demographic, clinical, laboratory, and hemody-
namic parameters, cannulation strategies, and outcomes including
complications, and weaning were collected. The primary binary end-
point was survival to discharge. The study was approved by the New
York Methodist Hospital Institutional Review Board (Board Ref #
1382246; date of approval 2/5/2019). The requirement for individual
patient consent was waived.
Patients underwent VA-ECMO for cardiogenic shock or cardiac
arrest in the setting of postcardiotomy shock, acute myocardial
infarction/ischemic cardiomyopathy, nonischemic cardiomyopathy,
or rarely pulmonary or other etiologies. Cardiogenic shock was typi-
cally defined as 1) a systolic blood pressure of less than 90 mmHg
despite the use of maximum doses of vasopressors (norepinephrine
32mcg/min, epinephrine 20mcg/min, and vasopressin 0.04 U/.min),
2) a cardiac index less than 2.0 l/m/m2 despite the use of inotropic
agents and other forms of mechanical support including intraaortic
balloon pump (IABP) counterpulsation or impella (Abiomed, Danvers,
MA), 3) elevated filling pressures including pulmonary capillary
wedge pressure greater than 16 mmHg or central venous pressure
greater than 18 mmHg, or pulmonary edema on chest xray, and 4)
evidence of end organ malperfusion including oliguria, elevated lac-
tate levels and markers of renal or hepatic dysfunction. Pre-ECMO
hemodynamic and laboratory variables collected were the last value
available within 24 h of VA-ECMO placement. A creatinine level of
4 mg/dL was assigned to any patient on hemodialysis at the time of
VA-ECMO cannulation. Contraindications for VA-ECMO included the
presence of 1) advanced age (>80 years), 2) neurologic injury, 3)
active bleeding or absolute contraindications to anticoagulation, 4)
active malignancy, 5) prolonged downtime after cardiac arrest
(>30 min prior to ECMO team activation), 6) severe sepsis (hypoten-
sion, tachycardia, hyperthermia or hypothermia, and end organ dys-
function secondary to a known or suspected infection), or any other
factor thought to represent a profound limitation of life expectancy.
Neurological injury is difficult to quantify in shock patients as they
are typically intubated and sedated. However, any patient who, at
the last assessable time, was documented to not wake up when off
sedation, open eyes, move extremities, and follow commands or who
demonstrates abnormal brainstem reflexes would be considered at
risk for neurologic injury. The final decision to institute VA-ECMO
was made by the treating physicians including cardiothoracic sur-
geons, interventional and heart failure cardiologists, and cardiac
intenstivists.
The VA-ECMO circuit consisted of either the Biomedicus
(Abiomed, Danvers, MA) or the Centrimag (Levitronix, Waltham, MA)
pump and a Quadrox D oxygenator (Maquet, Wayne, NJ). Femoral,
axillary, and central aortic arterial cannulation and femoral, internal
jugular, and central right atrial venous cannulation strategies were
utilized depending the clinical scenario and surgeon preference. Bed-
side femoral cannulation was most commonly performed in emer-
gent scenarios precluding patient transfer as in the intensive care
unit or emergency room, or in the cardiac catheterization suite at the
time of percutaneous coronary intervention. Central aortic and right
atrial cannulation was most commonly used in the setting of postcar-
diotomy shock after cardiac surgery in the operating room. Axillary
cannulation was utilized semi-electively when a patient failed to
wean from femoral VA-ECMO as a preferred long-term cannulation
strategy to allow for patient mobilization or in the setting of lower
extremity vascular complications secondary to femoral cannulation.
Ipsilateral antegrade limb perfusion sheaths as a general institutional
policy were used in all cases of femoral cannulation, either by percu-
taneous placement with or without ultrasound guidance or via surgi-
cal cutdown. If unable to be placed, and the limb thought to be
ischemic, the patient was converted from femoral to another cannu-
lation access strategy. Patients were heparinized to an activated clot-
ting time of 250 s for cannulation and maintained at a partial
thromboplastin time of 4560 s during the course of VA-ECMO sup-
port except in the presence of bleeding complications or severe coa-
gulopathy secondary to thrombocytopenia or hepatic dysfunction
with an elevated international normalized ratio, in which case hepa-
rin dosages were reduced or held.
Scores for three previously existing survival prediction models for
critically ill patients including the APACHE II score, the SAPS II score,
and the SOFA score, as well as for patients undergoing elective car-
diac surgey, the ACEF score, were calculated for all patients in the
current study. Scores for two additional survival prediction models
designed for patients undergoing VA-ECMO, the Save and the Encour-
age scores were also calculated for all patients.
Statistical analysis
Continuous variables were described as the mean and compared
with the students t-test. Categorical variables were described as fre-
quency and percentages and compared with the chi squared test or
fisher exact test as appropriate. All variables were assessed for corre-
lation with survival to discharge on univariate analysis. APACHE II,
SAPS, SOFA, ACEF, Encourage, and Save scores were calculated for all
patients.
Predictive accuracy was assessed on univariate analysis and using
the area under the receiver operating characteristic (ROC) curve. The
ROC maps the true positive rate (sensitivity) versus the false positive
rate (1-specificity) of a given test. As the sensitivity (y-axis) increases,
the false positive rate (1-specificity; x-axis) will increase (to catch
Table 1
Pre-cannulation patient characterestics.
Survival to discharge (n)%*
Overall No (31) Yes (20) p
Age (years) 57 57.7 56 .75
Female 23 (46) 16 (52) 7 (35) .24
Body surface area m2 1.86 1.83 1.89 .35
Ecpr 21 (41) 14 (45) 7 (35) .47
Cardiac arrest 37 (73) 23 (74) 14 (70) .74
Downtime (minutes) 30 35 20 .14
Etiology .66
Postcardiotomy shock 13 (25) 9 (29) 4 (20)
Ischemic cardiomyopathy 20 (39) 10 (32) 10 (50)
Nonischemic cardiomyopathy 14 (27) 9 (29) 5 (25)
Other (%) 4 (8) 3 (10) 1 (5)
Postcardiotomy shock (%) 13 (25) 9 (29) 4 (20) .53
Mechanical ventilation time (days) 1.7 2.7 .2 .15
Lactate (mmol/L) 10.2 10.9 9.2 .36
Ph 7.2 7.2 7.2 .79
Bicarbonate (mmol/L) 19.7 20 19.1 .64
Albumin (g/dL) 3 2.8 3.2 .17
Total bilirubin (mg/dL) 2 2.3 1.5 .29
Alanine aminotransferase (unit/L) 414 506 281 .44
Aspartate aminotransferase (unit/L) 666 854 393 .27
Creatinine (mg/dL) 1.8 2.1 1.3 .02
PO2 (mmHg) 149 134 171 .32
Platelet count (K/uL) 182 164 210 .14
International normalized ratio 1.9 2.0 1.8 .59
White blood cell count (K/uL) 16.4 18.5 11.1 .05
Hematocrit (%) 33.6 31.8 36.3 .09
Ejection fraction (%) 40 40 39 .90
* Unless otherwise indicated.
ECPR: extracorporeal cardiopulmonary resuscitation.
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more patients with the disease, one will inadvertently include more
patients without the disease). In a totally useless test, the false posi-
tive rate will increase in a linear fashion with sensitivity, leading to a
diagonal line on the graph. The better the test, the further to the left
the curve will lie from that diagonal line (sensitivity will increase a
lot with a minor increase in the false positive rate), and the area
under the curve (AUC) between the curve and the diagonal line will
be greater. Thus, a larger AUC represents a better test or score.
A p value of 0.05 or less was considered significant. All analyses
were performed with Stata 13 (StataCorp LLC College Station, TX).
Results
Between 2010 and 2017, 51 patients underwent VA ECMO place-
ment for cardiogenic shock or cardiac arrest at our institution. Mean
age was 57 years and 46% were female. Indications for VA-ECMO sup-
port included postcardiotomy shock after cardiac surgery in 25%,
ischemic cardiomyopathy (including acute myocardial infarction) in
39%, nonischemic cardiomyopathy in 27%, and other etiolgies in 8%.
Cardiac arrest prior to VA-ECMO occurred in 73% with an average
downtime of 30 min, and 41% of patients underwent cannulation
during cardiac arrest (ECPR  extracorporeal cardiopulmonary resus-
citation). Peripheral cannulation was utilized in 94% of cases, and
central aortic/right atrial cannulation in 6%. Of those undergoing
peripheral cannulation, 96% were via femoral cannulation and 4%
were via axillary cannulation. Of those undergoing initial femoral
cannulation, 7% underwent conversion to central or axillary cannula-
tion for a variety of reasons, including lower extremity ischemia, dif-
ferential cyanosis, or to allow for mobilization.
Pre-ECMO factors significantly associated with survival to dis-
charge included creatinine level (2.1 vs 1.3 mg/dL; p = .02) and white
blood cell count (18.5 vs 11.1 K/uL; p = .05). Demographic, hemody-
namic, and laboratory parameters are listed in Table 1. While age
wasn’t associated with survival to discharge, very advanced age was
detrimental as no patient over the age of 75 years survived to dis-
charge (seven patients). Similarly, while disease chronicity (as deter-
mined by duration of pre-ECMO mechanical ventilation) wasn’t
associated with survival to discharge, very prolonged periods of ill-
ness were detrimental as no patient with a duration of pre-ECMO
mechanical ventilation of five or more days survived to discharge
(five patients).
Patients remained on VA-ECMO support for an average of
7.5 days. Two patients underwent emergent cardiac surgery while on
VA ECMO support (one coronary artery bypass surgery and one pul-
monary embolectomy). Both remained on VA-ECMO support postop-
eratively and did not survive to discharge. One patient was weaned
from VA-ECMO support, and underwent subsequent mitral valve
replacement and coronary artery bypass grafting and survived to dis-
charge. Fifty-three percent of patients were successfully weaned
from VA-ECMO support, and of these, 74% survived to discharge.
Overall survival to discharge was 39% (Table 2).
Observed survival rates for all scores tested weakly paralleled
expected survival rates, although the correlation was strongest for
the APACHE II and Encourage scores (Figs. 12). On univariate analy-
sis, three survival prediction model scores were significantly higher
in nonsurvivors to discharge than survivors; the Encourage score
(25.4 vs 20; p = .04), the APACHE II score (23.6 vs 19.2; p = .05), and
the ACEF score (3.1 vs 1.8; p = .03 [Table 3]). In ROC curve analysis,
the ACEF score demonstrated the greatest predictive ability with an




Average length of ECMO support 7.52 days
Weaned from ECMO 27 (53)
Survival to discharge 20 (39)
Overall survival 15 (29)
* Unless otherwise indicated.
ECMO: extracorporeal membrane oxygenation.
Fig. 1. (a) Expected versus observed survival according to APACHE II score (APACHE II: acute physiology and chronic health evaluation II). (b) Expected versus observed survival
according to SOFA score (SOFA: sequential organ failure assessment). (c) Expected versus observed survival according to SAPS II score (SAPS II: simplified acute physiology II)
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Discussion
In the current analysis, a variety of survival prediction models
were assessed for their ability to predict outcomes in a cohort of
patients undergoing VA-ECMO support for cardiogenic shock. The
Encourage score, APACHE II score, and the ACEF score were signifi-
cantly associated with survival to discharge, while the SAPS, SOFA
and SAVE scores demonstrated no difference between survivors and
nonsurvivors. Of the three former scores, the ACEF score demon-
strated the strongest discriminatory ability by ROC analysis.
VA-ECMO is increasingly utilized in the setting of cardiogenic
shock or cardiac arrest to restore hemodynamic stability and end-
organ function. VA-ECMO serves as a short term ventricular assist
device that can be rapidly placed at the bedside in the emergency
room, intensive care unit, cardiac catheterization suite, or operating
room. A bridge to decision approach allows for the assessment of
neurologic status, renal and hepatic function, and subsequent recov-
ery of cardiac function. Further treatment is tailored appropriately,
including bridging to percutaneous coronary intervention or cardiac
surgery, recovery with decannulation, long term implantable left
ventricular assist device or heart transplant in the setting of adequate
end organ function but inadequate cardiac recovery, or withdrawal
of care in the unfortunate setting of irreversible multiorgan failure or
neurologic injury.




Overall No (31) Yes (20) p
Save score 7.1 8 5.9 .21
Encourage score 23.3 25.4 20 .04
SAPS score 55.2 56.7 52.9 .37
SOFA score 10.5 11 9.8 .35
APACHE II score 21.9 23.6 19.2 .05
ACEF score 2.6 3.1 1.8 .03
ACEF; age, creatine, ejection fraction, APACHE II: acute physiol-
ogy and chronic health evaluation II, SAPS II: simplified acute
physiology II, SOFA:sequential organ failure assessment.
Table 4




SAPS II score .59
SOFA score .56
APACHE II score .65
ACEF score .70
ACEF; age, creatine, ejection fraction, APACHE II:
acute physiology and chronic health evaluation II,
SAPS II: simplified acute physiology II, SOFA:sequen-
tial organ failure assessment.
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Despite its life-saving potential, VA-ECMO is fraught with compli-
cations including vascular complications from cannulation. In addi-
tion, neurologic injury, renal failure, liver failure, and sepsis are all
well described sequelae of the post-cardiogenic shock or cardiac
arrest VA-ECMO patient.2-4 Allocation of this heroic resource to those
most likely to benefit is crucial in order to appropriately allocate lim-
ited precious financial and human resources as well as to avoid pro-
longing patient suffering and the associated emotional trauma
inflicted on the family in the setting of medical futility.15
Age, lactate levels, etiology of cardiogenic shock, end-organ func-
tion, and prior cardiac arrest are all known to predict survival after
VA-ECMO.5-9,13-14 However, the circumstances surrounding a patient
in cardiogenic shock or cardiac arrest with regards to the need for an
immediate risk profile assessment in the setting of incomplete or no
information creates unique challenges.16
The APACHE II, SAPS II, and SOFA scores are widely described scores
used to predict hospital survival in critically ill patients admitted to the
intensive care unit (ICU). All three utilize a combination of hemody-
namic and laboratory variables, age, and neurologic status (glasgow
coma scale [GCS]) on admission to the ICU. They have been externally
validated in a variety of settings. In patients undergoing institution of
VA-ECMO support, variable results were demonstrated, with AUCs rang-
ing from 0.5 to 0.7. In the current study, similar findings were noted.
Although the APACHE II score did demonstrate significant differences
between survivors and nonsurvivors and the SAPS II and SOFA scores
did not, all demonstrated only modest discriminatory ability with AUCs
in the same range as prior studies. However, these scores were not
derived from, nor intended to predict outcomes in VA-ECMO patients.
Several survival prediction models for severe respiratory failure
requiring venovenous ECMO have been devised.17-21 Only a few such
models exist for VA-ECMO. Schmidt et al. created the SAVE scoring
system utilizing the Extracorporeal Life Support Organization (ELSO)
registry to predict survival to discharge in VA-ECMO patients.5 While
incorporating a large number of patients from a registry, limitations
include exclusion of ECPR patients and the cumbersome nature of the
score, which requires several variables to calculate. ECPR patients
represent a unique subgroup of patients undergoing VA-ECMO sup-
port with regards to neurologic outcome, the degree of end organ
dysfunction, and also the technical difficulty of obtaining access in a
pulseless patient rapidly. The ENCOURAGE score was created utilizing
a bi-institutional database and predicts survival to ICU discharge in
VA-ECMO patients.7 While the model demonstrated good discrimina-
tory power, it was somewhat cumbersome for use in the emergent
setting and is only applicable to patients in cardiogenic shock from
acute myocardial infarction.
In the current study, although the Encourage score did demonstrate
significant differences between survivors and nonsurvivors and the
SAVE score did not, both demonstrated similar discriminatory ability
with AUCs in the same range (0.61 and 0.66, respectively). Not surpris-
ingly, in the original study from which the Encourage was derived,
strong discriminatory ability was demonstrated with an AUC of 0.84.7
Pabst. et al. attempted to improve on the score by creating
a modified version replacing “prothrombin activity h 50%” with an
“INR i 200, and demonstrated an AUC of 0.74, slightly higher than in the
current study.13 Interestingly, in the original study by Schmidt et al. in
which the SAVE score was derived, only a modest discriminatory abil-
ity was noted in the ELSO registry derivation cohort of 3846 patients
with an AUC of 0.68. However, in their validation cohort of 161
patients from a single institution, excellent discriminatory ability with
an AUC of 0.9 was noted.5 A subsequent study by Chen at. al. attempt-
ing to modify the SAVE score to predict survival of emergency depart-
ment patients undergoing institution of VA-ECMO support found an
AUC of 0.73 for the original SAVE score, although this was improved to
0.84 by incorporating lactate into a “modified” SAVE score.6 The origi-
nal Encourage score study demonstrated an AUC of 0.71 for the SAVE
score.7 Our results with regards to these scores designed specifically
for patients undergoing institution of VA-ECMO support are in accor-
dance with these prior results. They demonstrate only a modest dis-
criminatory ability, not much improved over those scores designed for
critically ill patients in general (APACHE II, SAPS, SOFA).
The ACEF score was designed to predict mortality after elective
cardiac surgery.22 The score is calculated by taking the ratio of the
age in years and the ejection fraction, and adding one point if the cre-
atinine is >2 mg/dL. Interestingly, although the only score in the cur-
rent analysis not designed to predict mortality in critically ill
patients, the ACEF score demonstrated the best discriminatory ability.
This is likely due to significant overlap in risk factors commonly cor-
related with outcomes after elective cardiac surgery (age, ejection
fraction, and renal function) VA-ECMO. Furthermore, it is by far the
simplest of the above scores to determine, requiring only three easily
obtainable variables to calculate. One major limitation occurs in the
setting of eCPR, in which case the baseline ejection fraction is likely
Fig. 3. Area under the receiver operating characteristic curves (ACEF: age, creatinine, and ejection fraction; APACHE II: acute physiology and chronic health evaluation II; SAPS II:
simplified acute physiology II; SOFA: sequential organ failure assessment).
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to be unknown. Another limitation is that it oversimplifies the
complex clinical scenario of most patients under consideration for
VA-ECMO as the chronicity (or lack thereof) of cardiomyopathy or
renal failure are not taken into account, nor are other factors associ-
ated with active shock. Acute derangements are more of an indication
of the need for VA-ECMO, whereas acute derangements that will not
be corrected and suggest a poor overall prognosis are contraindications.
Other risk prediction models for cardiac surgery including the
Society of Thoracic Surgeons Predicted Risk of Mortality Score (STS-
PROM) or the EuroScore are widely used to predict outcomes after
elective or emergent cardiac surgery but are not practical to calculate
in the emergent setting of a patient undergoing evaluation for insti-
tution of VA-ECMO support.
Future research will need to be conducted utilizing larger datasets
to better analyze the risks associated with poor outcomes on VA
ECMO support to allow for creation of more accurate risk prediction
models. Modifying current registries or creating new ones with the
addition of more granular data and incorporating methods to audit
such registries to ensure accuracy of data will be crucial to devise
such scores in a useful way.
Limitations of this study include those inherent to a retrospective
analysis utilizing chart review including incomplete data, potential
inaccuracies in data, and potential for selection bias. In particular,
determining the GCS of critically ill patients in cardiogenic shock or
cardiac arrest, who are frequently intubated and sedated, by retro-
spective chart review is subject to error. A major limitation was the
small sample size, and the inhomogenous nature of the patient
cohort. In addition, due to differences in clinical practice across cen-
ters, extrapolation of results may be of limited value.
Conclusions
Mortality after VA-ECMO as a salvage therapy for cardiogenic
shock remains high. A variety of survival prediction model scores
designed for critically ill ICU patients and VA-ECMO patients demon-
strated a weak to modest discriminatory ability in the current cohort
of patients undergoing institution of VA-ECMO support for a variety
of indications. The ACEF score, while not designed to predict survival
in emergent scenarios, demonstrated the best, albeit only a modest
degree of discriminatory ability. Furthermore, it is by far the simplest
to calculate, an advantage in the setting of an acutely decompensat-
ing or arresting patient requiring rapid decision making. Further
studies are greatly needed with regards to risk prediction models for
patients undergoing institution of VA-ECMO support as no optimal
currently available model exists, but the current study suggests that
simpler may be better.
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